Subepithelial lesions (SELs) of the upper gastrointestinal tract are found in about 1 in 300 endoscopies, and in over two-thirds of cases are located in the stomach. They are a heterogeneous group of lesions comprising both non-neoplastic and neoplastic pathology. The list includes lipomas, leiomyomas, gastrointestinal stromal tumours (GISTs), neural origin lesions such as schwannomas, neuromas, neurofibromas and granular cell tumours, and neuroendocrine tumours. Additionally, there are lymphomas, cysts, metastases, inflammatory polyps, varices and some other miscellaneous pathologies.
Lipomas are benign and arise from the submucosa, typically having a yellowish appearance with a so-called “pillow sign” on touching with forceps. Leiomyomas arise from the muscularis propria and represent over 75% of SELs found in the oesophagus. They are typically benign, comprised of smooth muscle cells and fibrous connective tissue, and can be reviewed by endoscopic ultrasound (EUS). Surveillance is generally not required for leiomyomas in the oesophagus or stomach. Leiomyosarcomas are malignant muscle tumours and are extremely rare. Ectopic pancreatic tissue is a benign developmental anomaly located generally in the antrum and requiring no follow-up.
Neuroendocrine tumours (NETs) arise from neuroendocrine cells in the mucosa and submucosa. Type 1 NETs develop in a background of chronic atrophic gastritis where parietal cell loss leads to persistent hypergastrinemia and enterochromaffin-like (ECL) cell hyperplasia. Assessment of gastrin levels, B12, anti-intrinsic factor and anti-parietal cell antibodies, as well as thyroid assessment (frequent comorbidity), is advised. Ki-67 is a key cellular marker used to grade the proliferation activity and hence malignant potential of NETs.
Cystic gland polyps, also called fundic gland polyps, are frequently found in the stomach and are linked to proton pump inhibitor usage. They are not classified as SELs, and hundreds of such polyps may arise in FAP syndrome.
Granular cell tumours are SELs thought to arise from Schwann cells and are found in the oesophagus, oral cavity and tongue. These are usually solitary, and less than 2% are malignant.
Gastrointestinal stromal tumours, or GISTs, were first described in 1983 and arise from the cells of Cajal – the so-called pacemaker cells found in the muscularis propria. About 40–70% of GISTs are found in the stomach, and about 20–40% are located in the small intestine.
GISTs can be examined further by EUS and biopsy, and prognosis is determined by size and the number of cell mitoses. Surgical resection is generally recommended for any GIST greater than 2 cm in diameter. The tyrosine kinase inhibitor imatinib is used in both neoadjuvant and adjuvant roles.
We are joined by upper gastrointestinal surgeon Dr Hamish Shilton to review this subject. Hamish performs upper gastrointestinal surgery through predominantly laparoscopic and robotic techniques, including management of oesophageal neoplasia by minimally invasive oesophagectomy, hiatal hernia repair, cholecystectomy and bariatric surgery.
He completed subspecialty training in both Auckland and Norwich at high-volume bariatric and oesophageal cancer units. He works at Cabrini Hospital Malvern and also has an appointment at Monash Health Melbourne. Please welcome Hamish to the podcast.
References
Hwang, J. H., & Kimmey, M. B. (2004). The incidental upper gastrointestinal subepithelial mass. Gastroenterology, 126(1), 301–307. https://doi.org/10.1053/j.gastro.2003.11.040